Solventum (SOLV) Expected to Release Earnings on Wednesday

Solventum (NYSE:SOLV) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $1.91 per share and revenue of $2.1540 billion for the quarter. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.34 earnings per share. On average, analysts expect Solventum to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Solventum Stock Performance

Shares of SOLV traded up $0.82 during mid-day trading on Wednesday, reaching $86.99. 148,694 shares of the company’s stock were exchanged, compared to its average volume of 1,402,368. The business’s fifty day simple moving average is $77.78 and its 200-day simple moving average is $74.17. The stock has a market capitalization of $15.07 billion, a PE ratio of 10.66, a price-to-earnings-growth ratio of 1.24 and a beta of 0.66. Solventum has a 52-week low of $62.38 and a 52-week high of $88.20. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75.

Analyst Ratings Changes

SOLV has been the topic of several research reports. BTIG Research reissued a “buy” rating and set a $91.00 price objective on shares of Solventum in a research report on Monday, July 13th. Piper Sandler decreased their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. BMO Capital Markets initiated coverage on Solventum in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Wedbush assumed coverage on Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 price objective for the company. Finally, Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $86.00.

Institutional Investors Weigh In On Solventum

A number of hedge funds have recently added to or reduced their stakes in SOLV. Quadrant Capital Group LLC acquired a new position in Solventum during the third quarter worth $86,000. Wilkerson Advisory Group LLC acquired a new stake in Solventum in the fourth quarter valued at $68,000. Smartleaf Asset Management LLC lifted its holdings in Solventum by 23.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock valued at $60,000 after acquiring an additional 142 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Solventum during the 4th quarter worth $55,000. Finally, T. Rowe Price Investment Management Inc. boosted its position in shares of Solventum by 1,482.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 538 shares of the company’s stock worth $43,000 after purchasing an additional 504 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.